New drug offers hope to free elderly patients from steroid side effects
NCT ID NCT07072988
Summary
This study is testing whether a newer drug called efgartigimod can help elderly patients with generalized myasthenia gravis reduce their steroid doses. Myasthenia gravis causes muscle weakness, and steroids are commonly used but cause serious side effects like diabetes and high blood pressure. Researchers will follow 50 patients aged 65+ for 12 months to see if switching to efgartigimod allows them to safely lower their steroid use while still controlling their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nice
RECRUITINGNice, Alpes-Maritimes, 06000, France
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.